Insight Molecular Diagnostics INC. (IMDX) — SEC Filings

Overview

Insight Molecular Diagnostics INC. (IMDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 20, 2026: On April 16, 2026, Broadwood Partners, L.P. reported a change in beneficial ownership of securities for Insight Molecular Diagnostics Inc. The filing details transactions related to their holdings, with Broadwood Capital Inc. and Neal C. Bradsher also listed as reporting entities. The filing was acc

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 2 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Insight Molecular Diagnostics INC. is neutral.

Filing Type Overview

Insight Molecular Diagnostics INC. (IMDX) has filed 1 4, 6 10-Q, 24 8-K, 3 DEF 14A, 1 S-1, 2 10-K, 4 SC 13G/A, 3 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• Broadwood Partners Reports Ownership Change in Insight Molecular Diagnostics — 4 · Apr 20, 2026 Risk: medium
  On April 16, 2026, Broadwood Partners, L.P. reported a change in beneficial ownership of securities for Insight Molecular Diagnostics Inc. The filing details tr
• IMDX Revenue Soars 638% Amidst Continued Losses, Strategic Rebrand — 10-Q · Nov 10, 2025 Risk: high
  Insight Molecular Diagnostics Inc. (IMDX) reported a significant increase in net revenue for the nine months ended September 30, 2025, reaching $2.916 million,
• Insight Molecular Diagnostics Files 8-K — 8-K · Nov 10, 2025 Risk: low
  Insight Molecular Diagnostics Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial State
• Insight Molecular Diagnostics Inc. Files 8-K on Officer/Director Changes — 8-K · Oct 2, 2025 Risk: medium
  Insight Molecular Diagnostics Inc. filed an 8-K on October 2, 2025, reporting events as of September 28, 2025. The filing primarily concerns the departure of di
• Insight Molecular Diagnostics Inc. Announces Board and Officer Changes — 8-K · Sep 19, 2025 Risk: low
  Insight Molecular Diagnostics Inc. announced on September 16, 2025, changes in its board and officer composition, including the election of new directors and ap
• Insight Molecular Diagnostics Files 8-K — 8-K · Aug 11, 2025 Risk: low
  Insight Molecular Diagnostics Inc. filed an 8-K on August 11, 2025, reporting on its Results of Operations and Financial Condition. The filing also includes Fin
• IMDX Q2 Loss Widens to $10.9M Amid Revenue Dip — 10-Q · Aug 11, 2025 Risk: high
  Insight Molecular Diagnostics Inc. (IMDX) reported a net loss of $10.9 million for the three months ended June 30, 2025, a significant increase from the $7.8 mi
• Insight Molecular Diagnostics Inc. Files 8-K on Shareholder Vote — 8-K · Jul 2, 2025 Risk: low
  Insight Molecular Diagnostics Inc. filed an 8-K on July 2, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 27, 20
• Oncocyte Corp. Files 8-K with Corporate Updates — 8-K · Jun 17, 2025 Risk: low
  On June 13, 2025, Oncocyte Corp. filed an 8-K report detailing amendments to its Articles of Incorporation and Bylaws, along with Regulation FD disclosures and
• Oncocyte Corp Files Definitive Proxy Statement — DEF 14A · May 14, 2025 Risk: low
  Oncocyte Corp filed a Definitive Proxy Statement (DEF 14A) on May 14, 2025. The filing indicates no fee was required for this submission. The company's principa
• Oncocyte Corp Files 8-K on Financials — 8-K · May 12, 2025 Risk: low
  On May 12, 2025, Oncocyte Corporation filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financ
• Oncocyte Corp Files 10-Q for Q1 2025 — 10-Q · May 12, 2025 Risk: medium
  Oncocyte Corp filed a 10-Q for the period ending March 31, 2025. The company, formerly known as OncoCyte Corp, is involved in diagnostic substances. Key dates m
• Oncocyte Corp Changes Independent Accountant — 8-K · Apr 17, 2025 Risk: medium
  Oncocyte Corporation announced on April 11, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public ac
• Oncocyte Corp Files S-1 for Securities Registration — S-1 · Mar 28, 2025 Risk: medium
  Oncocyte Corporation filed an S-1 form on March 28, 2025, indicating a registration for securities. The company, incorporated in California with its principal e
• Oncocyte Corp Files 8-K on Financials — 8-K · Mar 24, 2025 Risk: low
  On March 24, 2025, Oncocyte Corporation filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements an
• Oncocyte Corp Files 2024 10-K, Details Chronix Merger — 10-K · Mar 24, 2025 Risk: medium
  Oncocyte Corp filed its 2024 10-K on March 24, 2025, reporting its fiscal year ending December 31, 2024. The filing details the company's financial performance
• Oncocyte Corp Appoints New Directors, Updates Executive Contracts — 8-K · Mar 10, 2025 Risk: medium
  On March 4, 2025, Oncocyte Corporation announced changes in its board of directors and executive compensation. Specifically, the company elected two new directo
• Oncocyte Corp Files 8-K: Agreements, Sales, and Disclosures — 8-K · Feb 10, 2025 Risk: medium
  On February 6, 2025, Oncocyte Corporation entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. The
• Oncocyte Corp Enters Material Definitive Agreement — 8-K · Jan 8, 2025 Risk: medium
  On January 2, 2025, Oncocyte Corporation entered into a material definitive agreement. The filing does not provide specific details about the agreement or any a
• SC 13G/A Filing — SC 13G/A · Dec 9, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Oncocyte Corp Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
  On November 12, 2024, Oncocyte Corporation filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements
• Oncocyte Corp Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Oncocyte Corp filed its 10-Q for the period ending September 30, 2024. The company reported sales revenue for the nine months ended September 30, 2024, and the
• SC 13G/A Filing — SC 13G/A · Oct 24, 2024
• Oncocyte Corp Files 8-K on Director Changes & Compensation — 8-K · Oct 15, 2024 Risk: medium
  On October 11, 2024, Oncocyte Corporation filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing al
• SC 13G Filing — SC 13G · Oct 9, 2024
• Oncocyte Corp Files 8-K: Material Agreement, Equity Sales — 8-K · Oct 3, 2024 Risk: medium
  On October 2, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company
• Oncocyte Corp Files Definitive Proxy Statement — DEF 14A · Sep 25, 2024 Risk: low
  Oncocyte Corp filed a Definitive Proxy Statement (DEF 14A) on September 25, 2024. The filing indicates no fee was required for this submission. The company, pre
• Oncocyte Corp Files 8-K: Material Agreements Entered and Terminated — 8-K · Aug 9, 2024 Risk: medium
  On August 9, 2024, Oncocyte Corporation entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The filing does not pr
• Oncocyte Corp Files 10-Q for Q2 2024 — 10-Q · Aug 8, 2024 Risk: medium
  Oncocyte Corp filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key f
• Oncocyte Corp Faces Delisting Concerns — 8-K · Jul 12, 2024 Risk: high
  Oncocyte Corporation filed an 8-K on July 12, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest eve
• Oncocyte Corp to be Acquired — 8-K · Jul 5, 2024 Risk: medium
  Oncocyte Corporation announced on June 28, 2024, that it has entered into a definitive agreement to be acquired by a third party. The company also reported on t
• Oncocyte Corp Files 8-K: Board & Executive Changes — 8-K · Jun 17, 2024 Risk: medium
  On June 17, 2024, Oncocyte Corporation filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the depa
• Oncocyte Corp Elects New Directors, Reports Executive Compensation — 8-K · May 31, 2024 Risk: medium
  On May 30, 2024, Oncocyte Corporation announced the election of Dr. Jonathan P. S. Farber and Mr. David E. Bear to its Board of Directors. Additionally, the com
• Oncocyte Corp Appoints New Directors, Reports Executive Compensation — 8-K · May 23, 2024 Risk: medium
  On May 20, 2024, Oncocyte Corporation announced the election of Dr. Michael J. McShane and Mr. David L. Briones to its Board of Directors. Additionally, the com
• Oncocyte Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  Oncocyte Corp (IMDX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Oncocyte Corp filed a 10-Q report for the period ending March 31, 2024. The f
• Oncocyte Corp Schedules 2024 Annual Shareholder Meeting — DEF 14A · Apr 29, 2024 Risk:
  Oncocyte Corp (IMDX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Shareholders for Oncocyte Corporation will be
• SC 13G Filing — SC 13G · Apr 22, 2024
• 10-K Filing — 10-K · Apr 16, 2024
• Broadwood Partners Amends Oncocyte Stake — SC 13D/A · Apr 15, 2024 Risk: medium
  Broadwood Partners, L.P. has filed an amendment (No. 11) to its Schedule 13D concerning Oncocyte Corporation, as of April 15, 2024. The filing indicates changes
• Oncocyte Corp Files 8-K: Material Agreement, Financials, Equity Sales — 8-K · Apr 12, 2024 Risk: medium
  On April 11, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also report
• Oncocyte Corp Files 8-K: Material Agreement & Financials — 8-K · Apr 11, 2024 Risk: medium
  On April 5, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reporte
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Oncocyte Files 8-K for Jan 22 Event; Routine Disclosure — 8-K · Jan 23, 2024
  Oncocyte Corporation filed an 8-K on January 23, 2024, reporting an event that occurred on January 22, 2024. This filing is a routine disclosure under Regulatio

Related Companies

3M · ONC

Frequently Asked Questions